Navigation Links
Access Pharmaceuticals Raises $6.0 Million In Registered Direct Offering
Date:12/10/2010

DALLAS and NEW YORK, Dec. 10, 2010 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.  Additionally, at the closing, Access will issue to the investors warrants to purchase, in the aggregate, approximately 0.7 million shares of common stock at a price of $3.06 per share, which warrants are exercisable immediately for a term of 5 years from the closing date.  The initial closing of the offering is expected to take place subject to the satisfaction of customary closing conditions.

"In addition to providing Access capital to support the commercial launch of MuGard, this financing should prove to be a positive for Access investors as it also helps shore up our balance sheet for partnering discussions in our various programs," stated Jeffrey B. Davis, President & CEO.  He continued, "This additional funding from current and new investors will provide a strong foundation to continue executing on our multifaceted strategy for moving valuable assets within the company forward."

Hudson Securities, Inc., a subsidiary of Hudson Holding Corporation (OTC Bulletin Board: HDHL), acted as the Company's placement agent in connection with the offering. The common stock and warrants are being offered by Access pursuant to an effective registration statement(s) on Form S-1 filed with the Securities and Exchange Commission ("SEC").

This press rele
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cellectis bioresearch Signs Non-Exclusive License With Evrogen for Access to Fluorescent Proteins
2. ViroPharma Incorporated and Idis Partner to Facilitate International Access to Certain ViroPharma Therapeutics Through Named Patient Program
3. Access Pharmaceuticals Files Additional IP For Cobalamin Oral Delivery Technology
4. Dynamic Ventures Corporations Information To Be Available Through Standard & Poors Market Access Program
5. Castle Access Names New Managing Director
6. Full Agenda Announced for CBIs Commercialization and Market Access Congress (CMAC 2010)
7. Access Pharmaceuticals Furthers Progress on Its Cobalamin-mediated Targeted Drug Delivery Platform for siRNA
8. Cardium Gains Exclusive Access to Novel Polymer-Based Nitric Oxide Technology for Expansion of Wound Healing Product Portfolio
9. Access Pharmaceuticals Presents at American Chemical Society Annual Fall Meeting in Boston, MA
10. US Oncology Helps Deliver Latest Cancer Therapies Through Local Community Access to Cutting Edge Research
11. Orchestrall Sponsors China Business Toolbox: Brings Focus to the How and When of China Market Access
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed ... CoV virus strains has revealed extensive conservation and ... conservation and sharing of specific Replikin gene structures has ... as it did for the H5N1 influenza vaccine and ... been found to be effective (1,2). ...
(Date:8/26/2014)... just been added to the growing case for ... next big thing in the high-tech world by ... international collaboration of researchers led by a scientist ... Berkeley National Laboratory (Berkeley Lab) has reported the ... photo-excited MX2 materials. The recorded charge transfer time ...
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... 26, 2014 The global market for ... by 2020, according to a new study by Grand ... theranostics, and the subsequent introduction of advanced cancer diagnostic ... growth over the next six years. Moreover, the growing ... as cancer, coupled with disease triggering lifestyle habits such ...
Breaking Biology Technology:Competition for graphene 2ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 2World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 3World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 4World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 5World Molecular Diagnostics Market Is Expected To Grow To $8,020.1 Million From 2014 To 2020: Grand View Research, Inc 6
... , , , ... Pharmaceuticals, Inc. (Nasdaq: IDIX ), a biopharmaceutical company engaged ... human viral diseases, today announced the pricing of an underwritten offering ... $3.14 per share. After underwriting discounts and commissions and estimated offering ...
... - ImmunoVaccine Technologies Inc. (IVT), a Canadian vaccine ... Scancell Ltd., the operating company of Scancell Holdings ... infectious disease vaccines. This research agreement will explore ... for Scancell,s novel ImmunoBody(R) DNA vaccines. , "Scancell ...
... ... of Winter Park, Fla., will demonstrate how its partnership with AeroClave, LLC, can help ... produced can mitigate the threat of healthcare-associated infections such as MRSA and contagious pathogens ... , ...
Cached Biology Technology:Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock 2ImmunoVaccine Technologies Partners With Scancell to Advance DNA Vaccine Delivery 2Winter Park Home to World's Foremost Producers of Large-Scale Decontamination Equipment 2
(Date:8/26/2014)... policymakers, consumers, and suppliers has prompted manufacturers to ... pollutants they emit from their smokestacks or discharge ... assess environmental performance at every step in their ... the use and recycling of their products. , ... known as life cycle engineering, which connects the ...
(Date:8/26/2014)... nutrition (EN), or feeding patients through a tube, in ... still common. A practice of a certain amount of ... or emergencies. Changing to a volume-based system, which calls ... underfeeding. , Such a system was found to be ... audit published in the American Society for Parenteral and ...
(Date:8/26/2014)... suggested an increased risk of autism among children ... actually reflect the known increased risk associated with ... advance online publication in Molecular Psychiatry , ... while a diagnosis of autism spectrum disorder ... prescribed antidepressants during pregnancy than in those with ...
Breaking Biology News(10 mins):Yale journal explores advances in sustainable manufacturing 2Study calls into question link between prenatal antidepressant exposure and autism risk 2Study calls into question link between prenatal antidepressant exposure and autism risk 3
... emphasizes the development of a series of nested environment ... with the individual, and also affect the development of ... is the major source influencing human development, which is ... saw the individual,s experience "as a set of nested ...
... N. Kuggie Vallee Foundation announces, today, the first recipients ... are: Dr. Kirsty L. Spalding, Senior Researcher in ... Karolinska Institutet (Stockholm, Sweden) who studies obesity by investigating ... David Tobin, Assistant Professor of Molecular Genetics and Microbiology ...
... enhance mental energy and well-being not only for healthy ... according to a July 15 panel discussion at the ... Food Expo held at McCormick Place. Bonnie Kaplan, ... University of Calgary, Alberta, Canada, said Monday vitamins and ...
Cached Biology News:
Rabbit Serum New Zealand or California Origin...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... be returned to customer conjugation of peptide to KLH protein ... 102 days/each , Pre-immune bleed x1 /each ... , Test bleed (app. 5 ml) x1 /each ...
...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
Biology Products: